45 related articles for article (PubMed ID: 38627125)
21. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
Mandelker D; Donoghue M; Talukdar S; Bandlamudi C; Srinivasan P; Vivek M; Jezdic S; Hanson H; Snape K; Kulkarni A; Hawkes L; Douillard JY; Wallace SE; Rial-Sebbag E; Meric-Bersntam F; George A; Chubb D; Loveday C; Ladanyi M; Berger MF; Taylor BS; Turnbull C
Ann Oncol; 2019 Aug; 30(8):1221-1231. PubMed ID: 31050713
[TBL] [Abstract][Full Text] [Related]
22. Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches.
Roggia C; Armeanu-Ebinger S; Gschwind A; Seibel-Kelemen O; Hertler S; Faust U; Liebmann A; Haack TB; Neumann M; Bonzheim I; Forschner A; Kopp HG; Herster F; Hartkopf A; Bitzer M; Malek NP; Brecht IB; Ruhm K; Möller Y; Löwenheim H; Ossowski S; Rieß OH; Schroeder C
Eur J Cancer; 2023 Jan; 179():48-55. PubMed ID: 36495689
[TBL] [Abstract][Full Text] [Related]
23. The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.
McVeigh TP; Sundar R; Diamantis N; Kaye SB; Banerji U; Lopez JS; de Bono J; van der Graaf WTA; George AJ
Eur J Cancer; 2018 May; 95():20-29. PubMed ID: 29614442
[TBL] [Abstract][Full Text] [Related]
24. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
Truong H; Breen K; Nandakumar S; Sjoberg DD; Kemel Y; Mehta N; Lenis AT; Reisz PA; Carruthers J; Benfante N; Joseph V; Khurram A; Gopalan A; Fine SW; Reuter VE; Vickers AJ; Birsoy O; Liu Y; Walsh M; Latham A; Mandelker D; Stadler ZK; Pietzak E; Ehdaie B; Touijer KA; Laudone VP; Slovin SF; Autio KA; Danila DC; Rathkopf DE; Eastham JA; Chen Y; Morris MJ; Offit K; Solit DB; Scher HI; Abida W; Robson ME; Carlo MI
Eur Urol; 2023 Jan; 83(1):29-38. PubMed ID: 36115772
[TBL] [Abstract][Full Text] [Related]
25. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
Waszak SM; Northcott PA; Buchhalter I; Robinson GW; Sutter C; Groebner S; Grund KB; Brugières L; Jones DTW; Pajtler KW; Morrissy AS; Kool M; Sturm D; Chavez L; Ernst A; Brabetz S; Hain M; Zichner T; Segura-Wang M; Weischenfeldt J; Rausch T; Mardin BR; Zhou X; Baciu C; Lawerenz C; Chan JA; Varlet P; Guerrini-Rousseau L; Fults DW; Grajkowska W; Hauser P; Jabado N; Ra YS; Zitterbart K; Shringarpure SS; De La Vega FM; Bustamante CD; Ng HK; Perry A; MacDonald TJ; Hernáiz Driever P; Bendel AE; Bowers DC; McCowage G; Chintagumpala MM; Cohn R; Hassall T; Fleischhack G; Eggen T; Wesenberg F; Feychting M; Lannering B; Schüz J; Johansen C; Andersen TV; Röösli M; Kuehni CE; Grotzer M; Kjaerheim K; Monoranu CM; Archer TC; Duke E; Pomeroy SL; Shelagh R; Frank S; Sumerauer D; Scheurlen W; Ryzhova MV; Milde T; Kratz CP; Samuel D; Zhang J; Solomon DA; Marra M; Eils R; Bartram CR; von Hoff K; Rutkowski S; Ramaswamy V; Gilbertson RJ; Korshunov A; Taylor MD; Lichter P; Malkin D; Gajjar A; Korbel JO; Pfister SM
Lancet Oncol; 2018 Jun; 19(6):785-798. PubMed ID: 29753700
[TBL] [Abstract][Full Text] [Related]
26. Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing.
Al-Shinnag M; Cheong PL; Goodwin A; Trent R; Yu B
Pathology; 2024 Jun; 56(4):468-472. PubMed ID: 38627125
[TBL] [Abstract][Full Text] [Related]
27. Investigating the role of somatic sequencing platforms for phaeochromocytoma and paraganglioma in a large UK cohort.
Winzeler B; Tufton N; S Lim E; Challis BG; Park SM; Izatt L; Carroll PV; Velusamy A; Hulse T; Whitelaw BC; Martin E; Rodger F; Maranian M; Clark GR; A Akker S; Maher ER; Casey RT
Clin Endocrinol (Oxf); 2022 Oct; 97(4):448-459. PubMed ID: 34870338
[TBL] [Abstract][Full Text] [Related]
28. Primer on Hereditary Cancer Predisposition Genes Included Within Somatic Next-Generation Sequencing Panels.
Akras Z; Bungo B; Leach BH; Marquard J; Ahluwalia M; Carraway H; Grivas P; Sohal DPS; Funchain P
JCO Precis Oncol; 2019 Dec; 3():1-11. PubMed ID: 35100683
[TBL] [Abstract][Full Text] [Related]
29. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
[TBL] [Abstract][Full Text] [Related]
30. Landscape of somatic mutated genes and inherited susceptibility genes in gynecological cancer.
Watanabe T; Soeda S; Okoshi C; Fukuda T; Yasuda S; Fujimori K
J Obstet Gynaecol Res; 2023 Nov; 49(11):2629-2643. PubMed ID: 37632362
[TBL] [Abstract][Full Text] [Related]
31. The emerging significance of secondary germline testing in cancer genomics.
Mandelker D; Zhang L
J Pathol; 2018 Apr; 244(5):610-615. PubMed ID: 29293272
[TBL] [Abstract][Full Text] [Related]
32. Investigation of clinically relevant germline variants detected by next-generation sequencing in patients with childhood cancer: a review of the literature.
Sylvester DE; Chen Y; Jamieson RV; Dalla-Pozza L; Byrne JA
J Med Genet; 2018 Dec; 55(12):785-793. PubMed ID: 30287599
[TBL] [Abstract][Full Text] [Related]
33. Somatic mutation panels: Time to clear their names.
Trottier AM; Cavalcante de Andrade Silva M; Li Z; Godley LA
Cancer Genet; 2019 Jun; 235-236():84-92. PubMed ID: 31101556
[TBL] [Abstract][Full Text] [Related]
34. Germline and somatic drivers in inherited hematologic malignancies.
Zoller J; Trajanova D; Feurstein S
Front Oncol; 2023; 13():1205855. PubMed ID: 37904876
[TBL] [Abstract][Full Text] [Related]
35. Identifying potential germline variants from sequencing hematopoietic malignancies.
Kraft IL; Godley LA
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):219-227. PubMed ID: 33275754
[TBL] [Abstract][Full Text] [Related]
36. Identifying potential germline variants from sequencing hematopoietic malignancies.
Kraft IL; Godley LA
Blood; 2020 Nov; 136(22):2498-2506. PubMed ID: 33236764
[TBL] [Abstract][Full Text] [Related]
37. Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?
Cussenot O; Cancel-Tassin G; Rao SR; Woodcock DJ; Lamb AD; Mills IG; Hamdy FC
BJU Int; 2023 Nov; 132(5):472-484. PubMed ID: 37410655
[TBL] [Abstract][Full Text] [Related]
38. BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell CL; Salih Z; Woodward ER; Lalloo F; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
Br J Cancer; 2022 Jul; 127(1):163-167. PubMed ID: 35260807
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
